Abstract

Introduction: Microtubules play an important role in several cellular processes, particularly in the formation of the mitotic spindle during the process of mitosis. These highly dynamic mitotic-spindle microtubules have become a successful target of cancer therapy. Microtubule-targeting agents, such as vinca alkaloids and taxanes, were used in clinic over 50 years. In past decades, development of new antimicrotubule agents that possess different structure and binding sites of tubulin has shown potent activity against the proliferation of various cancer cells, as well as in multidrug-resistant cancers. Interestingly, many of these agents represent an attractive ability that targeting the tumor blood vessels results in tumor vascular disruption. Therefore, exploring new agents and strategies may provide more effective therapeutic options in the related treatment of cancer. Areas covered: In past few years, there are many chemical compounds that successfully interferes the microtubules and display antitumor effect. In these, published compounds supply the fresh minds in modification of present drugs and new insights into the development of tubulin inhibitors. Expert opinion: This article arranges the microtubule-targeting agents that have published in patent in recent years. It may help in the investigation of new tubulin binding site and development of novel drug candidate in the future.

Original languageEnglish
Pages (from-to)69-88
Number of pages20
JournalExpert Opinion on Therapeutic Patents
Volume24
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Tubulin Modulators
Microtubules
Spindle Apparatus
Tubulin
Neoplasms
Binding Sites
Vinca Alkaloids
Vascular Tissue Neoplasms
Taxoids
Second Primary Neoplasms
Expert Testimony
Mitosis
Pharmaceutical Preparations
Blood Vessels
Therapeutics

Keywords

  • Cancer
  • Combretastatin
  • Microtubule
  • Mitosis
  • Tubulin
  • Vascular disrupting

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Tubulin inhibitors : A patent review. / Liu, Yi Min; Chen, Hsiao Ling; Lee, Hsueh Yun; Liou, Jing Ping.

In: Expert Opinion on Therapeutic Patents, Vol. 24, No. 1, 01.2014, p. 69-88.

Research output: Contribution to journalArticle

@article{a53beea301154061b8f3ec54da83b198,
title = "Tubulin inhibitors: A patent review",
abstract = "Introduction: Microtubules play an important role in several cellular processes, particularly in the formation of the mitotic spindle during the process of mitosis. These highly dynamic mitotic-spindle microtubules have become a successful target of cancer therapy. Microtubule-targeting agents, such as vinca alkaloids and taxanes, were used in clinic over 50 years. In past decades, development of new antimicrotubule agents that possess different structure and binding sites of tubulin has shown potent activity against the proliferation of various cancer cells, as well as in multidrug-resistant cancers. Interestingly, many of these agents represent an attractive ability that targeting the tumor blood vessels results in tumor vascular disruption. Therefore, exploring new agents and strategies may provide more effective therapeutic options in the related treatment of cancer. Areas covered: In past few years, there are many chemical compounds that successfully interferes the microtubules and display antitumor effect. In these, published compounds supply the fresh minds in modification of present drugs and new insights into the development of tubulin inhibitors. Expert opinion: This article arranges the microtubule-targeting agents that have published in patent in recent years. It may help in the investigation of new tubulin binding site and development of novel drug candidate in the future.",
keywords = "Cancer, Combretastatin, Microtubule, Mitosis, Tubulin, Vascular disrupting",
author = "Liu, {Yi Min} and Chen, {Hsiao Ling} and Lee, {Hsueh Yun} and Liou, {Jing Ping}",
year = "2014",
month = "1",
doi = "10.1517/13543776.2014.859247",
language = "English",
volume = "24",
pages = "69--88",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Tubulin inhibitors

T2 - A patent review

AU - Liu, Yi Min

AU - Chen, Hsiao Ling

AU - Lee, Hsueh Yun

AU - Liou, Jing Ping

PY - 2014/1

Y1 - 2014/1

N2 - Introduction: Microtubules play an important role in several cellular processes, particularly in the formation of the mitotic spindle during the process of mitosis. These highly dynamic mitotic-spindle microtubules have become a successful target of cancer therapy. Microtubule-targeting agents, such as vinca alkaloids and taxanes, were used in clinic over 50 years. In past decades, development of new antimicrotubule agents that possess different structure and binding sites of tubulin has shown potent activity against the proliferation of various cancer cells, as well as in multidrug-resistant cancers. Interestingly, many of these agents represent an attractive ability that targeting the tumor blood vessels results in tumor vascular disruption. Therefore, exploring new agents and strategies may provide more effective therapeutic options in the related treatment of cancer. Areas covered: In past few years, there are many chemical compounds that successfully interferes the microtubules and display antitumor effect. In these, published compounds supply the fresh minds in modification of present drugs and new insights into the development of tubulin inhibitors. Expert opinion: This article arranges the microtubule-targeting agents that have published in patent in recent years. It may help in the investigation of new tubulin binding site and development of novel drug candidate in the future.

AB - Introduction: Microtubules play an important role in several cellular processes, particularly in the formation of the mitotic spindle during the process of mitosis. These highly dynamic mitotic-spindle microtubules have become a successful target of cancer therapy. Microtubule-targeting agents, such as vinca alkaloids and taxanes, were used in clinic over 50 years. In past decades, development of new antimicrotubule agents that possess different structure and binding sites of tubulin has shown potent activity against the proliferation of various cancer cells, as well as in multidrug-resistant cancers. Interestingly, many of these agents represent an attractive ability that targeting the tumor blood vessels results in tumor vascular disruption. Therefore, exploring new agents and strategies may provide more effective therapeutic options in the related treatment of cancer. Areas covered: In past few years, there are many chemical compounds that successfully interferes the microtubules and display antitumor effect. In these, published compounds supply the fresh minds in modification of present drugs and new insights into the development of tubulin inhibitors. Expert opinion: This article arranges the microtubule-targeting agents that have published in patent in recent years. It may help in the investigation of new tubulin binding site and development of novel drug candidate in the future.

KW - Cancer

KW - Combretastatin

KW - Microtubule

KW - Mitosis

KW - Tubulin

KW - Vascular disrupting

UR - http://www.scopus.com/inward/record.url?scp=84890407835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890407835&partnerID=8YFLogxK

U2 - 10.1517/13543776.2014.859247

DO - 10.1517/13543776.2014.859247

M3 - Article

C2 - 24313741

AN - SCOPUS:84890407835

VL - 24

SP - 69

EP - 88

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 1

ER -